A Study of the Effectiveness and Safety of Dapoxetine in the Treatment of Men With Premature Ejaculation.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00211107|
Recruitment Status : Completed
First Posted : September 21, 2005
Last Update Posted : May 19, 2011
|Condition or disease||Intervention/treatment||Phase|
|Ejaculation||Drug: Dapoxetine||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||1294 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A Placebo-Controlled, Double-Blind, Randomized, Parallel Study Of The Efficacy And Safety Of Dapoxetine HCl In The Treatment Of Rapid Ejaculation|
|Study Start Date :||June 2003|
|Actual Study Completion Date :||June 2004|
- Average intravaginal ejaculatory latency time (IELT), as measured by stopwatch during sexual intercourse, between last 2 visits during the treatment period
- Control over ejaculation, satisfaction with sexual intercourse, and severity of symptom impressions, based on questions asked at start of study and through Week 12; incidence, severity, and type of adverse events throughout study (12 weeks).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00211107
|Study Director:||Alza Corporation Clinical Trial||ALZA|